Medicamen Biotech Ltd

Dividend record date and book closure

• Purpose: determine entitlement to the Final Dividend for FY2025-26 at the 33rd AGM.
• Security: equity shares.
• Book closure: Sep 20–26, 2026 (both days inclusive).
• Record date: Sep 19, 2026 for dividend payment.
• Dividend: final dividend recommended by board, subject to shareholder approval.
• Payment timeline: payment to shareholders on record date, subject to applicable laws.

Dividend and meeting dates

• Final dividend of 10% (Re 1 per equity share) subject to shareholder approval.
• Register and transfer books closed Sept 19–25, 2026 for dividend entitlement.
• e-voting window Sept 23–25, 2026; AGM on Sept 26, 2026 via VC/OAVM.

AGM & Voting Details

• Security: Equity shares.
• 33rd AGM on Sep 26, 2026 at 12:00 PM via VC/OAVM.
• Cut-off date for e-voting eligibility: Sep 19, 2026.
• EVoting window: Sep 23-25, 2026.
• Register and transfer books closed Sep 19-25, 2026.

Results & Compliance

• Unaudited standalone and consolidated Q1 FY2026 results approved.
• Draft Annual Report for FY2025-26 approved.
• Draft Cost Audit Report for FY2025-26 approved.
• Total fine payable for non-compliance: ₹110,920 incl. GST.
• Payment to exchanges completed on 02-Jun-2026.

Financial highlights

• Standalone net sales / income from operations: 4,385.27 (Three Month Period Ended 30.06.2026, Unaudited).
• Standalone total revenue: 4,471.43 (Three Month Period Ended 30.06.2026, Unaudited).
• Consolidated net sales / income from operations: 4,789.69 (Three Month Period Ended 30.06.2026, Unaudited).
• Consolidated total revenue: 4,875.85 (Three Month Period Ended 30.06.2026, Unaudited).
• Standalone PBT before tax: 325.79 (Three Month Period Ended 30.06.2026, Unaudited).
• Consolidated PBT before tax: 257.17 (Three Month Period Ended 30.06.2026, Unaudited).
• Standalone total comprehensive income net of tax: 252.69 (Three Month Period Ended 30.06.2026).
• Consolidated total comprehensive income net of tax: 184.60 (Three Month Period Ended 30.06.2026).
• Auditors' limited reviews issued with unmodified opinions.

Dividend & AGM

• Final dividend: 10% (Rs 1 per share) subject to member approval.
• AGM scheduled for Sep 26, 2026 via VC/OAVM.
• Record date fixed Sep 19, 2026; evoting Sep 23–25, 2026.

Regulatory & governance

• Draft Annual Report FY2025-26 and Draft Cost Audit Report FY2025-26 approved.
• Fines for SEBI/Exchange non-compliance: Rs 110,920 including GST; payment made on June 2, 2026.

Business scope

• Group operates in Pharmaceuticals; single segment.
• Subsidiaries: Opal Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited.

Meeting Details

• Date: Aug 14, 2026; Time: not disclosed; Location: Registered Office, 1506 Chiranjiv Tower, Nehru Place, New Delhi.

Key Agenda Items

• Unaudited standalone and consolidated financial results for quarter ended June 30, 2026.
• Draft Annual Report for the financial year 2025-26.
• Draft Cost Audit Report for the financial year 2025-26.

Other Notes

• Trading window closed for designated persons from July 1, 2026; opens 48 hours after results.

Dematerialisation status

• The dematerialised/rematerialised securities have been listed on the stock exchanges.
• Certificates were mutilated and cancelled after verification, with the depository substituted as registered owner within 30 days.